Abstract
Background: Neonatal pneumonia is a common disease in the neonatal period with a high incidence and death. This study aimed to investigate the molecular mechanism and effect of microRNA (miR)-429 in neonatal pneumonia.
Methods: The peripheral blood was collected from neonatal pneumonia and healthy patients, respectively. Human lung fibroblast WI-38 cells were treated with lipopolysaccharide (LPS) to establish neonatal pneumonia cell model. Then, the miR-429 expression was detected by quantitative real-time polymerase chain reaction (qRT-PCR). In addition, the relationship between miR- 429 and kruppel-like factor 4 (KLF4) was confirmed by dual luciferase reporter assay. Cell viability, the level of interleukin 6 (IL-6), IL-1β and tumor necrosis factor α (TNF-α) and apoptosis were measured by Cell Counting Kit-8 (CCK-8), enzyme linked immunosorbent assay (ELISA) and flow cytometry. Meanwhile, apoptosis and nuclear factor kappa-B (NF-κB) pathway related proteins expression were analyzed by western blot.
Results: MiR-429 expression level was increased in neonatal peripheral blood and LPS-stimulated WI-38 cells. Then, miR-429 overexpression increased apoptosis, the level of IL-6, IL-1β, TNF-α, Bax and cleaved caspase-3, while reduced cell viability in LPS-stimulated WI-38 cells. Besides, KLF4 was identified as the target gene of miR-429, and reversed the changes caused by miR-429 overexpression. Finally, miR-429 suppressor down-regulated p-NF-κB level in LPS-stimulated cells and KLF4 knockdown reversed these reductions.
Conclusion: MiR-429 promotes inflammatory injury, apoptosis and activates the NF-κB signaling pathway by targeting KLF4 in neonatal pneumonia, and then these results provide evidence for clinical diagnosis and treatment for neonatal pneumonia.
Keywords: Neonatal pneumonia, miR-429, kruppel-like factor 4 (KLF4), apoptosis, inflammatory injury, lipopolysaccharide (LPS).
[http://dx.doi.org/10.1097/INF.0b013e3181958755] [PMID: 19106760]
[http://dx.doi.org/10.1186/1471-2458-11-S3-S13] [PMID: 21501430]
[http://dx.doi.org/10.1136/adc.2003.048108] [PMID: 15846010]
[PMID: 23234773]
[PMID: 11851052]
[http://dx.doi.org/10.1111/j.1440-1754.2010.01814.x] [PMID: 20796185]
[PMID: 20422339]
[http://dx.doi.org/10.1007/s10067-015-2898-x] [PMID: 25736037]
[http://dx.doi.org/10.1042/BJ20131510] [PMID: 26431850]
[http://dx.doi.org/10.1016/j.ajpath.2010.11.021] [PMID: 21224073]
[http://dx.doi.org/10.1074/jbc.M700078200] [PMID: 17339326]
[http://dx.doi.org/10.1016/j.bbrc.2009.12.002] [PMID: 19968965]
[http://dx.doi.org/10.1183/09031936.00196311] [PMID: 22653776]
[http://dx.doi.org/10.1002/jcp.24402] [PMID: 23696417]
[http://dx.doi.org/10.1074/jbc.M112.433730] [PMID: 23430263]
[http://dx.doi.org/10.1158/0008-5472.CAN-12-0667] [PMID: 22593189]
[PMID: 25270210]
[http://dx.doi.org/10.1016/j.bbrc.2018.04.109] [PMID: 29673591]
[http://dx.doi.org/10.1016/j.jbo.2016.02.002] [PMID: 27335771]
[http://dx.doi.org/10.1515/jomb-2015-0019] [PMID: 28356874]
[http://dx.doi.org/10.3892/mmr.2014.2675] [PMID: 25322940]
[http://dx.doi.org/10.1002/1873-3468.12502] [PMID: 27883176]
[http://dx.doi.org/10.1016/j.bbrc.2014.05.084] [PMID: 24866238]
[http://dx.doi.org/10.1371/journal.pone.0087780] [PMID: 24523873]
[http://dx.doi.org/10.1038/srep17577] [PMID: 26627732]
[http://dx.doi.org/10.1002/jcp.25300] [PMID: 26728119]
[http://dx.doi.org/10.14423/SMJ.0000000000000362] [PMID: 26539945]
[http://dx.doi.org/10.3892/or.2017.5507] [PMID: 28440423]
[http://dx.doi.org/10.1371/journal.pone.0054806] [PMID: 23372771]
[http://dx.doi.org/10.18632/oncotarget.9141] [PMID: 27153563]
[http://dx.doi.org/10.1038/cdd.2015.85] [PMID: 26113043]
[http://dx.doi.org/10.1074/jbc.M509378200] [PMID: 16169848]